Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Lonza Group has been a dominant player in the contract development and manufacturing space for decades. We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

On the anniversary of Marisa Tufaro's passing, the foundation bearing her name made a generous donation to support pediatric ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...